Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01909466 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
NCT01909466 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 141 participants.
The verdict
NCT01909466, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
To determine the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult subjects with schizophrenia
Interventions
- DRUG Aripiprazole, OPC-14597
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01909466
The ClinicalTrials.gov registry entry for NCT01909466 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole, OPC-14597 is the first listed.
NCT01909466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01909466 about?
NCT01909466 is a clinical study titled "Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia". To determine the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult subjects with schizophrenia
What is the current status of trial NCT01909466?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2013-07. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01909466?
The interventions under investigation include: Aripiprazole, OPC-14597 (DRUG).
Who is sponsoring clinical trial NCT01909466?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.